MIRCERA, methoxy polyethylene glycol-epoetin beta, is an ESA which differs from erythropoietin through formation of a chemical bond between an amino group present in erythropoietin beta and methoxy polyethylene glycol (PEG) butanoic acid. MIRCERA
ثبت نشده
چکیده
There is a global increase in the number of patients with CKD. Data from the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) registry, in which roughly 80% of patients were on haemodialysis (HD) and 20% on peritoneal dialysis (PD), showed that the incidence of renal replacement therapy for ESRD had risen from 79 per million population (pmp) in 1990 to 117 pmp in 1999. More recent data from 2000-2003 has revealed an average European rate of 135 pmp.
منابع مشابه
Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease
BACKGROUND There is data in the literature indicating increased oxidative stress in chronic kidney disease (CKD). Erythropoiesisstimulating agents (ESAs), which are commonly used to treat anemia in patients with CKD, seem to have an antioxidant action, which could be a part of nephroprotection. The aim of the current study was to investigate the effect of a long half-life ESA, methoxy polyethyl...
متن کاملMethoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease
Chronic kidney disease (CKD) is a risk factor for end-stage renal failure and cardiovascular events. In patients with CKD, anemia is often caused by decreased erythropoietin production relative to hemoglobin levels. As correction of anemia is associated with improved cardiac and renal function and quality of life, erythropoiesis-stimulating agents (ESAs) are standard therapy for anemia in CKD p...
متن کاملAnemia treatment in patients with chronic kidney disease.
Anemia develops in most persons with progressive chronic kidney disease. When it becomes severe, the administration of erythropoiesisstimulating agents (ESAs) is generally required, along with the repletion of iron stores and the correction of other causes of anemia. The introduction of ESAs 30 years ago markedly improved the lives of many patients with chronic kidney disease, who until then ha...
متن کاملDose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
INTRODUCTION There is limited information published on switching erythropoiesis-stimulating agent (ESA) treatment for anemia associated with chronic kidney disease (CKD) from darbepoetin alfa (DA) to methoxy polyethylene glycol-epoetin beta (PEG-Epo) outside the protocol of interventional clinical studies. AFFIRM (Aranesp Efficiency Relative to Mircera) was a retrospective, multi-site, observat...
متن کاملMaintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial
BACKGROUND Several studies with erythropoiesis-stimulating agents claim that maintenance therapy of renal anaemia may be possible at extended dosing intervals; however, few studies were randomized, results varied, and comparisons between agents were absent. We report results of a multi-national, randomized, prospective trial comparing haemoglobin maintenance with methoxy polyethylene glycol-epo...
متن کامل